Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Avon Technologies Plc (AVNBF)
USD22.49
+0.00 (+0.00%)
GB OTC Healthcare Medical - Specialties
Address
Hampton Park West SN12 6NB
Melksham, GB
Melksham, GB
CEO
Mark Josceline Sclater
Website
avon-protection-plc.com
IPO
2012-08-15
ISIN GB0000667013
Also trades on
London Stock Exchange · AVON.L (GBp)
Other OTC · AVNBF (USD)
Description
Avon Technologies Plc focuses on developing and manufacturing protective breathing apparatus for military and industrial applications. Additionally, the company produces polymer-based materials tailored for the dairy and defense industries. Its business is structured around two core divisions: Respiratory Protection and Head Protection. Founded in 1885, the firm maintains its headquarters in Melksham, United Kingdom.
News Sentiment (7d)
Based on only 1 article — low confidence
- Avon Technologies wins $10.8m NATO respirator order Proactive Investors
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD22.49
+0.00 (+0.00%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
288
Beta
0.21
Float Shares
28.52M
Free Float %
96.8%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -7.20% | -13.85% | -13.85% | -11.33% | -12.61% | -9.06% | +20.77% | +87.82% | -50.80% | +49.33% | +1,020.00% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (3 ratings, all time)
Hold
Price Targets & DCF
Current price
22.49
DCF (Levered)
8.84
-60.7%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Quality scores
Altman Z-Score
4.79
Safe zone
Piotroski F-Score
8 / 9
Strong
MOAT Score
1 / 10
No MOAT
Composite Rating
B-
Overall Score
3 / 5
Medium
DCF Score
3 / 5
Medium
ROE Score
3 / 5
Medium
ROA Score
4 / 5
High
D/E Score
2 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Specialties: +8.3%-12.6% Q1'26: +218.6% (vs Q1'24)
-
EPS growth Medical - Specialties: +10.1%+165.9% ★ Q1'26: +2,375.9% (vs Q1'24)
-
FCF margin FCF growth · Medical - Specialties: +51.3%+1.4% Q1'26: -0.2% (vs Q1'24)
-
EBIT margin Medical - Specialties: +12.6%+6.1% Q1'26: +13.4% (vs Q1'24)
-
ROIC Medical - Specialties: +6.6%+4.9% Q1'26: +25.8% (vs Q1'24)
-
Share dilution Medical - Specialties: 0.0%0.0% ★ Q1'26: +2.3% (vs Q1'24)
-
Debt / EBITDA Net debt/EBITDA · Medical - Specialties: -0.39×2.67× Q1'26: 0.72× (vs Q1'24)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Sep 2015 actual |
Sep 2016 actual |
Sep 2017 actual |
Sep 2018 actual |
Sep 2019 actual |
Sep 2020 actual |
Sep 2021 actual |
Sep 2022 actual |
Sep 2023 actual |
Sep 2024 actual |
Sep 2025 actual |
Sep 2026 6 Rev. Ana. 1 EPS Ana. |
Sep 2027 6 Rev. Ana. 1 EPS Ana. |
Sep 2028 2 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
203.55M
est: 206.70M (-1.5%)
|
142.90M
est: 184.25M (-22.4%)
|
159.20M
est: 218.70M (-27.2%)
|
165.50M
est: 212.61M (-22.2%)
|
128.40M
est: 222.53M (-42.3%)
|
168.00M
est: 265.71M (-36.8%)
|
183.22M
est: 250.00M (-26.7%)
|
228.58M
est: 276.50M (-17.3%)
|
243.80M
est: 263.50M (-7.5%)
|
275.00M
est: 203.51M (+35.1%)
|
240.24M
est: 228.51M (+5.1%)
|
252.59M
251.39M – 254.78M
+10.5% YoY
|
269.70M
264.54M – 278.04M
+6.8% YoY
|
288.45M
284.94M – 294.27M
+7.0% YoY
|
| EBITDA |
40.58M
est: 19.55M (+107.6%)
|
30.00M
est: 17.43M (+72.2%)
|
36.40M
est: 20.68M (+76.0%)
|
34.40M
est: 20.11M (+71.1%)
|
20.77M
est: 21.05M (-1.3%)
|
31.50M
est: 25.13M (+25.3%)
|
-200.0K
est: 23.64M (-100.8%)
|
32.30M
est: 26.15M (+23.5%)
|
8.00M
est: 24.92M (-67.9%)
|
30.90M
est: 16.78M (+84.2%)
|
30.46M
est: 18.84M (+61.7%)
|
20.82M
20.72M – 21.00M
+10.5% YoY
|
22.23M
21.81M – 22.92M
+6.8% YoY
|
23.78M
23.49M – 24.26M
+7.0% YoY
|
| EBIT |
28.31M
est: -2.22M (+1,377.4%)
|
21.89M
est: -1.98M (+1,207.9%)
|
27.06M
est: -2.35M (+1,253.9%)
|
29.84M
est: -2.28M (+1,408.7%)
|
12.54M
est: -2.39M (+625.4%)
|
8.50M
est: -2.85M (+398.3%)
|
-29.60M
est: -2.68M (-1,004.2%)
|
10.50M
est: -2.96M (+454.1%)
|
-12.80M
est: -2.83M (-353.0%)
|
10.70M
est: -2.80M (+482.8%)
|
14.54M
est: -3.14M (+563.3%)
|
-3.47M
-3.50M – -3.45M
-10.5% YoY
|
-3.70M
-3.82M – -3.63M
-6.8% YoY
|
-3.96M
-4.04M – -3.91M
-7.0% YoY
|
| Net Income |
20.71M
est: 15.71M (+31.8%)
|
17.60M
est: 19.98M (-11.9%)
|
21.50M
est: 19.92M (+7.9%)
|
20.30M
est: 22.67M (-10.4%)
|
17.58M
est: 26.51M (-33.7%)
|
1.60M
est: 27.53M (-94.2%)
|
-25.28M
est: 15.11M (-267.3%)
|
-6.81M
est: 1.41M (-581.4%)
|
-14.40M
est: 6.89M (-309.1%)
|
3.00M
est: 14.89M (-79.9%)
|
7.88M
est: 18.92M (-58.3%)
|
27.82M
27.38M – 28.55M
+47.1% YoY
|
31.22M
30.73M – 32.04M
+12.2% YoY
|
34.95M
34.40M – 35.87M
+11.9% YoY
|
| SGA |
40.63M
est: 82.07M (-50.5%)
|
41.44M
est: 73.16M (-43.4%)
|
47.56M
est: 86.84M (-45.2%)
|
49.90M
est: 84.42M (-40.9%)
|
26.60M
est: 88.36M (-69.9%)
|
74.60M
est: 105.50M (-29.3%)
|
107.80M
est: 99.27M (+8.6%)
|
67.70M
est: 109.79M (-38.3%)
|
88.30M
est: 104.63M (-15.6%)
|
81.00M
est: 75.15M (+7.8%)
|
73.32M
est: 84.39M (-13.1%)
|
93.28M
92.84M – 94.09M
+10.5% YoY
|
99.60M
97.69M – 102.68M
+6.8% YoY
|
106.52M
105.23M – 108.67M
+7.0% YoY
|
| EPS |
0.69
est: 0.51 (+34.7%)
|
0.58
est: 0.65 (-11.0%)
|
0.71
est: 0.65 (+9.3%)
|
0.67
est: 0.74 (-9.4%)
|
0.46
est: 0.86 (-46.8%)
|
0.23
est: 0.90 (-74.4%)
|
-0.83
est: 0.49 (-268.5%)
|
-0.25
est: 0.05 (-642.3%)
|
-0.48
est: 0.22 (-313.7%)
|
0.10
est: 0.49 (-79.4%)
|
0.27
est: 0.62 (-56.2%)
|
0.91
0.89 – 0.93
+47.1% YoY
|
1.02
1.00 – 1.05
+12.2% YoY
|
1.14
1.12 – 1.17
+11.9% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-14 | B- | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-12 | B- | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
43.00M
OE per share TTM
1.39
Owner's Yield
6.87%
Maintenance CapEx ratio
188.50%
Maint CapEx / Avg PPE
20.2%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
15.9K
Shares Outstanding
29.45M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Mark Josceline Sclater | Chief Executive Officer & Director | 2M | male |
| Richard John Cashin | Chief Financial Officer & Executive Director | 1M | male |
| James Wilcox | President of Team Wendy | — | male |
| Kate Vizmeg | Group HR Director | — | female |
| Kent Moeller | President of Avon Protection Ceradyne | — | — |
| Steve Elwell | President of Avon Protection | — | male |
| Chandlar Gabara | Continuous Improvement Leader | — | male |
| Zoe Elizabeth Holland | General Counsel & Company Secretary | — | female |
| Gary Dunn | Vice President of Sales & Marketing | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for AVNBF
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
